amifostine anhydrous has been researched along with lysine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bernard, B; Bijster, M; de Jong, M; Forrer, F; Krenning, EP; Rolleman, EJ; Valkema, R; Vermeij, M | 1 |
Anfossi, G; Barale, C; Cavalot, F; Doronzo, G; Mattiello, L; Pagliarino, A; Russo, I; Trovati, M; Viretto, M | 1 |
2 other study(ies) available for amifostine anhydrous and lysine
Article | Year |
---|---|
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Topics: Amifostine; Animals; Body Weight; Creatinine; Kidney; Lysine; Male; Neoplasms; Octreotide; Organometallic Compounds; Proteinuria; Radiation Injuries; Radiopharmaceuticals; Rats; Rats, Inbred Lew; Tomography, Emission-Computed, Single-Photon | 2007 |
High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets.
Topics: Adult; Amifostine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cell Adhesion Molecules; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Drug Resistance; Female; Humans; Hyperglycemia; Lysine; Male; Microfilament Proteins; Nitric Oxide; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Protein Processing, Post-Translational; Second Messenger Systems; Thromboxanes; Vasodilator Agents; Young Adult | 2012 |